Oral Herpes Treatments

Find Oral Herpes Treatments

Generic Name

Acyclovir

Brand Names
Avaclyr, Xerese, Zovirax
FDA approval date: March 29, 1982
Classification: Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor
Form: Ointment, Injection, Cream, Tablet, Suspension, Capsule

What is Avaclyr (Acyclovir)?

AVACLYR is a sterile topical antiviral indicated for the treatment of acute herpetic keratitis in patients with herpes simplex virus. AVACLYR 3%, a herpes simplex virus nucleoside analog DNA polymerase inhibitor, is indicated in the treatment of acute herpetic keratitis in patients with herpes simplex virus.

Approved To Treat

Top Global Experts

View All
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

Research on the Therapeutic Effect of Electroacupuncture on Acute Herpes Zoster-Associated Pain and Its Anti-inflammatory Injury Mechanism
Research on the Therapeutic Effect of Electroacupuncture on Acute Herpes Zoster-Associated Pain and Its Anti-inflammatory Injury Mechanism
Enrollment Status: Recruiting
Publish Date: June 16, 2026
Intervention Type: Drug, Procedure
Study Phase: Not Applicable

Background: Herpes zoster (HZ) is an acute dermatological condition caused by the varicella-zoster virus. Its onset is characterized by severe pain, imposing significant physical and psychological burdens on patients. Acupuncture offers distinct advantages in treating acute herpes zoster and associated pain. However, the therapeutic efficacy of electroacupuncture for acute herpes zoster, its potential to redu...

Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
Who is this study for: Patients with KSHV inflammatory cytokine syndrome
Enrollment Status: Recruiting
Publish Date: June 16, 2026
Intervention Type: Other, Drug
Study Drugs: Zidovudine, Liposomal Doxorubicin, Valganiclovir, Rituximab
Study Phase: Phase 2

Background: \- KSHV inflammatory cytokine syndrome (KICS) is a newly recognized disease caused by Kaposi sarcoma-associated herpesvirus (KSHV). This virus can cause cancer. People with KICS can have severe symptoms. They include fever, weight loss, and fluid in the legs or abdomen. People with KICS may also be at risk of getting other cancers associated with KSHV. These cancers include Kaposi sarcoma and lymp...

Epidemiological Burden of and Risk Factors for Ganciclovir Resistant/Refractory Cytomegalovirus in Solid Organ Transplant and Hematopoietic Stem Cell Transplant Patients: Multicentre Cohort Study
Epidemiological Burden of and Risk Factors for Ganciclovir Resistant/Refractory Cytomegalovirus in Solid Organ Transplant and Hematopoietic Stem Cell Transplant Patients: Multicentre Cohort Study
Enrollment Status: Recruiting
Publish Date: June 15, 2026

Summary: The ReCySOHT study is a multicenter, retrospective, observational case-control study on the risk factors for developing a ganciclovir-resistant/refractory (GCV-RR) cytomegalovirus infection in patients receiving solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). Aims of the study are to investigate the incidence of and risk factors for GCV-RR CMV infection in SOT recipients...

View All Clinical Trials

Related Latest Advances

A novel hollow-fiber infection model (HFIM) for antiviral PK/PD studies of CMV infection.
A novel hollow-fiber infection model (HFIM) for antiviral PK/PD studies of CMV infection.
Journal: Antimicrobial agents and chemotherapy
Published: June 18, 2026
Abdominal Pain Before Rash in Immunocompromised Patients: A Narrative Review of a Visceral Disseminated Varicella-Zoster Virus Infection.
Abdominal Pain Before Rash in Immunocompromised Patients: A Narrative Review of a Visceral Disseminated Varicella-Zoster Virus Infection.
Journal: Internal medicine (Tokyo, Japan)
Published: June 17, 2026
Reverse Transcriptase Activity with CRISPR (REACTR) Assay for Rapid and User-Friendly Therapeutic Drug Monitoring in Cytomegalovirus Care.
Reverse Transcriptase Activity with CRISPR (REACTR) Assay for Rapid and User-Friendly Therapeutic Drug Monitoring in Cytomegalovirus Care.
Journal: ACS infectious diseases
Published: June 16, 2026
View All Latest Advances

Brand Information

    Avaclyr (ACYCLOVIR)
    1INDICATIONS AND USAGE
    AVACLYR is a sterile topical antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus.
    2DOSAGE AND ADMINISTRATION
    The recommended dosing regimen is to apply a 1 cm ribbon of ointment in the lower cul-de-sac of the affected eye 5 times per day (approximately every 3 hours while awake) until the corneal ulcer heals and then a 1 cm ribbon 3 times per day for 7 days.
    3DOSAGE FORMS AND STRENGTHS
    AVACLYR is an ophthalmic ointment containing 3% acyclovir.
    4CONTRAINDICATIONS
    AVACLYR is contraindicated for patients who develop sensitivity to acyclovir or valacyclovir.
    5ADVERSE REACTIONS
    The most common adverse reactions (2-10%) reported in patients were eye pain (stinging), punctate keratitis and follicular conjunctivitis. Rare reports of blepharitis and very rare reports of immediate hypersensitivity reactions including angioedema and urticaria have been observed post-marketing in patients taking AVACLYR.
    6DRUG INTERACTIONS
    No clinically significant interactions have been identified resulting from topical administration of other drugs concomitantly with AVACLYR.
    7OVERDOSAGE
    Overdosage of topical application of acyclovir 3% is unlikely because of minimal absorption.
    8DESCRIPTION
    Acyclovir is a synthetic herpes simplex virus nucleoside analog DNA polymerase inhibitor. The drug substance is a white crystalline powder with the molecular formula of C
    The chemical name of acyclovir is 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]6H-purin-6-one, it has the following chemical structure:
    Chemical Structure
    AVACLYR is a sterile ointment for topical administration in eyes. Each gram of ointment contains 30 mg of acyclovir in a white petrolatum base.
    9CLINICAL STUDIES
    In five randomized, double masked studies which enrolled a total of 238 subjects with dendritic herpetic keratitis, acyclovir ophthalmic ointment, 3% was either superior or as effective as idoxuridine ophthalmic ointment 0.5% or 1% in subjects with dendritic ulcers. Clinical resolution (healed ulcers) at Day 7 averaged 83% for acyclovir and 50% for idoxuridine.
    10HOW SUPPLIED/STORAGE AND HANDLING
    AVACLYR is available in a 3.5 g aluminum tube with a white high density polyethylene cap as a clear, colorless, sterile ophthalmic ointment for topical use containing 3% acyclovir active drug. Each tube is packaged in an individual carton.
    3.5 g tube (NDC 48102-028-35)
    Store at 15°C to 25°C (59°F to 77°F).
    11Principal Display Panel - 30 mg Carton Label
    FERA
    NDC 48102-028-35
    Avaclyr®
    (Acyclovir
    For
    STERILE
    3.5g Net Wt. Rx only
    Principal Display Panel - 30 mg Carton Label
    12Principal Display Panel - 30 mg Tube Label
    FERA
    NDC 48102-028-35
    Avaclyr®
    (Acyclovir
    Each gram contains:
    acyclovir USP 30 mg
    For Topical
    Sterile
    3.5g Net Wt. Rx only
    Lot:
    Principal Display Panel - 30 mg Tube Label